Plasma extracellular vesicle tau, β-amyloid, and α-synuclein and the progression of Parkinson’s disease: a follow-up study
Open Access
- 1 January 2023
- journal article
- research article
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 16
Abstract
Background: Plasma extracellular vesicle (EV) contents are promising biomarkers of Parkinson’s disease (PD). The pathognomonic proteins of PD, including α-synuclein, tau, and β-amyloid, are altered in people with PD (PwP) and are associated with clinical presentation in previous cross-sectional studies. However, the dynamic changes in these plasma EV proteins in PwP and their correlation with clinical progression remain unclear. Objective: We investigated the dynamic changes in plasma EV α-synuclein, tau, and β-amyloid and their correlation with/prediction of clinical progression in PwP. Design: A cohort study. Methods: In total, 103 PwP and 37 healthy controls (HCs) completed baseline assessment and 1-year follow-up. Clinical assessments included Unified Parkinson’s Disease Rating Scale (UPDRS) parts II and III, Mini-Mental State Examination (MMSE), and Montreal Cognitive Assessment (MoCA). Plasma EVs were isolated, and immunomagnetic reduction-based immunoassay was used to assess α-synuclein, tau, and β-amyloid 1-42 (Aβ1-42) levels within the EVs. Results: Compared with HCs, significant differences were noted in the annual changes in all three EV pathognomonic proteins in PwP. Although the absolute changes in plasma EV pathognomonic proteins did not significantly correlate with clinical changes, PwP with elevated baseline plasma EV tau (upper-half) levels demonstrated significantly greater decline in motor and cognition, and increased plasma EV α-synuclein levels were associated with postural instability and the gait disturbance motor subtype. For PwP with elevated levels of all three biomarkers, clinical deterioration was significant, as indicated by UPDRS-II scores, postural instability and gait disturbance subscores of UPDRS-III, and MMSE score. Conclusion: The combination of plasma EV α-synuclein, tau, and Aβ1-42 may identify PwP with a high risk of deterioration. Our findings can elucidate the interaction between these pathognomonic proteins, and they may serve as treatment response markers and can be applied in treatment approaches for disease modification.Keywords
Funding Information
- Taipei Medical University-Shuang Ho Hospital (108TMU-SHH-12)
- National Taiwan University Hospital (111-UN0007)
- Minister of Science and Technology, Taiwan (MOST 110-2314-B-038-096)
- Parkinson Foundation (PF-CORE-855578)
This publication has 63 references indexed in Scilit:
- The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson's diseaseParkinsonism & Related Disorders, 2013
- Neuropathology of dementia in a large cohort of patients with Parkinson's diseaseParkinsonism & Related Disorders, 2013
- Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologiesNature Reviews Neuroscience, 2013
- Cognitive Impairment in Parkinson DiseaseJournal of Geriatric Psychiatry and Neurology, 2012
- Parkinson Subtypes Progress Differently in Clinical Course and Imaging PatternPLOS ONE, 2012
- The Parkinson Progression Marker Initiative (PPMI)Progress in Neurobiology, 2011
- Can focusing on UPDRS Part II make assessments of Parkinson disease progression more efficient?Nature Reviews Neurology, 2009
- Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodiesJournal of Neurology, Neurosurgery & Psychiatry, 2006
- Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approachJournal of Neurology, Neurosurgery & Psychiatry, 2005
- Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.Journal of Neurology, Neurosurgery & Psychiatry, 1992